FineHeart is a #French medical #device company focused on creating innovative #technologies in the #cardiovascular field. #HeartFailure #LVAD #SavingHearts" title="" class="btn" data-container="body" data-html="true" data-id="28866" data-placement="top" data-toggle="popover" data-trigger="focus" style="color:#b3d4fc" tabindex="0" data-original-title="FineHeart"> 282 5,459
Activities
Technologies
Entity types
Location
28 Av. Gustave Eiffel Bâtiment C, 33600 Pessac, France
Pessac
France
Employees
Scale: 51-200
Estimated: 75
SIREN
519375356Engaged corporates
29Added in Motherbase
5 years, 10 months agoA Healthier Life With Every Beat
FineHeart is a clinical stage medical device company based in Bordeaux, France. Its innovative product, FLOWMAKER®, has the potential to treat 200,000 patients with advanced heart failure each year. FineHeart will initially target the 50,000 most severe patients who are eligible for cardiac assistance. Initial estimates value this market segment to be worth over US$5 billion.
FineHeart was founded by CEO Arnaud Mascarell and a team of internationally renowned cardiac surgeons and electro-physiologists, including Dr. Stephane Garrigue, CSO and inventor of the concept, and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy (CRT). The company holds an international portfolio of 147 patents in 25 different families.
FineHeart benefits from the support of a wide range of public, private, industrial and independent investors: including the French groups Lauak and Doliam, FineHeart Founders, as well as the investment funds and historical shareholders Aquiti, Broadview Ventures, Galia, Irdi , M Capital, NACO, UI Investment, & Verve Ventures. FineHeart is also financed by the European Union (EIC), Bpifrance and the Nouvelle Aquitaine and Région Centre regions.
FLOWMAKER® is the first fully intraventricular, wireless flow accelerator that provides physiological support synchronized with the heart's natural contractions. It respects the natural blood flow and does not require aortic bypass surgery. It is the first miniaturized device - barely 10 cm in size - that is adjustable to patients' needs, like a pacemaker, to treat patients with varying degrees of severity. It has no external driveline as it is recharged via a wireless transcutaneous energy transfer system (TET). The device is implanted using a minimally invasive beating-heart procedure, commonly performed by cardiac surgeons, which, on average lasts 90 minutes.
cardiac assistance, implantable cardiac output management system, Medical device, Mechatronic Medicine, and Heart Failure
A Healthier Life With Every Beat
FineHeart is a french medical device company focused on creating innovative technologies in the cardiovascular space. The patented FineHeart invention, the ICOMS (Implantable Cardiac Output Management System) is a novel, wirelessly powered, fully implantable mechanical circulatory support device that is able to optimize cardiac output while preserving the heart’s innate contractility. It is a game changing therapy for long term circulatory assistance in severe heart failure patients.
Heart Failure (HF) is the second leading cause of death in the US and in Europe. It is a disease with high mortality rates, and repeated and extended hospitalizations. One out of every five patients die within the year following diagnosis. The average annual cost for the hospital to follow patients is up to €77K with 70% of the cost linked to hospitalization.
FineHeart was founded by a team of internationally renowned cardiologists and managers from the Medtech Industry, led by Arnaud Mascarell (CEO), Dr. Stéphane Garrigue (CSO) and Dr. Philippe Ritter, co-inventor of cardiac resynchronization therapy. Their vision became the FineHeart's mission: developing and offering to patients a miniaturized, fully implantable, pulsatile circulatory support system that would overcome many of the challenges associated with left ventricular assist devices (LVADs) currently on market. The overarching goal is to restore normal cardiac output and allow heart failure patients to return to a normal quality of life.
Our mission is to address the unmet need of patients with sever heart failure
Corporate | Type | Tweets | Articles | |
---|---|---|---|---|
![]() Pôle S2E2 Public business cluster, French Cluster, Business Consulting and Services | Pôle S2E2 Public business cluster, French Cluster, Business Consulting and Services | Not capitalistic Not partnership Event 24 Mar 2017 30 Mar 2024 | | |
![]() Centre-Val de Loire Region National and local authorities, Government Administration | Centre-Val de Loire Region National and local authorities, Government Administration | Not capitalistic Not partnership Event 24 Sep 2019 16 Feb 2025 | | |
![]() Bpifrance Bank, Banking | Bpifrance Bank, Banking | Not capitalistic Not partnership Event 16 Feb 2025 | | |
![]() MassChallenge Startup accelerator & VC, Venture Capital and Private Equity Principals | MassChallenge Startup accelerator & VC, Venture Capital and Private Equity Principals | Not capitalistic Not partnership Event 17 Feb 2017 | | |
![]() AQUITI Gestion Startup accelerator & VC, Venture Capital and Private Equity Principals | AQUITI Gestion Startup accelerator & VC, Venture Capital and Private Equity Principals | Not capitalistic Partnership Not event 29 Dec 2017 10 Sep 2022 | | |
![]() French Tech Bordeaux French Tech, IT Services and IT Consulting | French Tech Bordeaux French Tech, IT Services and IT Consulting | Not capitalistic Not partnership Event 5 Jul 2021 24 Sep 2024 | | |
![]() Cleantech Group Market Research | Cleantech Group Market Research | Not capitalistic Not partnership Event 10 Apr 2017 | | |
![]() UNITEC IT Services and IT Consulting | UNITEC IT Services and IT Consulting | Not capitalistic Not partnership Event 20 Sep 2018 10 Feb 2024 | | |
![]() Business France National and local authorities, Government Administration | Business France National and local authorities, Government Administration | Not capitalistic Not partnership Event 11 Feb 2022 25 Oct 2024 | | |